The effects of vitamin D therapy on left ventricular structure and function - Are these the underlying explanations for improved CKD patient survival?

Nephron - Clinical Practice

Volumn 116, Issue 3, 2010, Pages

  Covic, Adrian ^a   Voroneanu, Luminita ^a,c   Goldsmith, David ^b  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CI Parhon Hospital   (Romania)

Author keywords

Cardiac function; Chronic kidney disease; Vitamin D deficiency

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; RETINOID X RECEPTOR; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTERIAL STIFFNESS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; GENE TARGETING; GENETIC TRANSCRIPTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; NONHUMAN; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SURVIVAL; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT; VITAMIN SUPPLEMENTATION;

ANEMIA; ARTERIOSCLEROSIS; BONE AND BONES; CALCITRIOL; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HEART VENTRICLES; HUMANS; HYPERCALCEMIA; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; KIDNEY DISEASES; PARATHYROID HORMONE; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77954209876     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317198     Document Type: Short Survey

References (73)

1. Foley RN, Parfrey PS, et al: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000; 11: 912-916.
2. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354.
3. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol. Dial Transplant 1997; 12: 724-728.
4. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725.
5. Levin A, Thompson CR, Ethier et al: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
6. Tian JP, Wang T, Wang H, Cheng LT, Tian XK, Lindholm B, Axelsson J, Du FH: The prevalence of left ventricular hypertrophy in Chinese hemodialysis patients is higher than that in peritoneal dialysis patients. Ren Fail 2008; 30: 391-400.
7. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 2759-2767.
8. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.
9. Covic A, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ: Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. J Nephrol. 2006; 19: 783-793.
10. Shoji T, Shinohara K, Kimoto E, et al: Lower risk for cardiovascular mortality in oral 1- hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial Transplant 2004; 19: 179-184.
11. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37-43.
12. Shoji T, Nishizawa Y: Effects of vitamin D on non-classical target organs and survival. Clin Calcium 2007; 17: 691-697.
13. Baran DT, Quail JM, Ray R, Honeyman T: Binding of 1alpha,25- dihydroxyvitamin D(3) to annexin II: effect of vitamin D metabolites and calcium. J Cell Biochem 2000; 80: 259-265.
14. Adams JS, Hewison M: Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008; 4: 80-90.
15. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT: A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrin 2003; 17: 2386-2393.
16. Michos ED, Melamed ML: Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008; 11: 7-12.
17. Holick MF, Chen TC: Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87: 1080-1086.
18. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL: Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-783.
19. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T: A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcome of raloxifene evaluation trial. J Clin Endocrinol Metab 2001; 86: 1212-1221.
20. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S: Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577-582.
21. Pilz S, März W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H: Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. Clin Endocrinol Metab 2008; 93: 3927-3935.
22. Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, Reeve J, Warburton EA: Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-245.
23. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168: 1174-1180.
24. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M; Women s Health Initiative Investigators: Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
25. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
26. Rosenthal T: Seasonal variations in blood pressure. Am J Geriatr Cardiol 2004; 13: 267-273.
27. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007; 20: 713-719. (Pubitemid 46936167)
28. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
29. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
30. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
31. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288:E125-E132.
32. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH) 2 D 3 -dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
33. Simpson RU, Hershey SH, Nibbelink KA: Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-524.
34. Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU: 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103: 533-537.
35. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112.
36. Weishaar RE, Kim SN, Saunders DE, Simpson RU: Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258:E134-E142.
37. Wu J, Garami M, Cheng T, Gardner DG: 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588.
38. Längle F, Abela C, Koller-Strametz J, et al: Primary hyperparathyroidism and the heart: cardiac abnormalities correlated to clinical and biochemical data. World J Surg 1994;18: 619-624.
39. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU: Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007; 103: 416-419.
40. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-796.
41. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52: 660-673.
42. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH, Lee MH, Song HK, Cha DR, Kang SW, Han DS: Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 2006; 36: 377-338.
43. Helming L, Böse J, Ehrchen J, Schiebe S, Frahm T, Geffers R, Probst-Kepper M, Balling R, Lengeling A: 1alpha,25-dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106: 4351-4358.
44. Panichi V, De Pietro S, Andreini B, Bianchi AM, Migliori M, Taccola D, Giovannini L, Tetta C, Palla R: Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998; 54: 1463-1469.
45. Timms PM, Mannan N, Hitman GA, et al: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-796.
46. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
47. Ewers B, Gasbjerg A, Moelgaard C, Frederiksen AM, Marckmann P: Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 2008; 87: 431-437.
48. Ylikomi T, Laaksi I, Lou YR, et al: Antiproliferative action of vitamin D. Vitam Horm 2002; 64: 357-406.
49. Cardús A, Parisi E, Gallego C, Aldea M, Fernández E, Valdivielso JM: 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377-1384.
50. O Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU: 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272: H1751-1758.
51. Baksi SN, Hughes MJ: Deficiency in dietary vitamin D, not calcium, alters noradrenergic responsiveness in rat atria in vitro. J Mol Cell Cardiol 1986; 18: 653-656.
52. Kullo IJ, Bailey KR, McConnell JP, et al: Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension 2006; 47: 174-179.
53. Cozzolino M, Brancaccio D, Gallieni M, et al: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436.
54. Block GA, Spiegel DM, Ehrlich J, et al: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68: 1815-1824.
55. Wolisi, Godwin O, Moe MS: The role of vitamin D in vascular calcification in chronic kidney disease. Sem Dial 2005; 18: 307-314.
56. Cardus A, Panizo S, Parisi E, et al: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
57. Hirata M, Katsumata K, Endo K, et al: In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH) 2 vitamin D 3 . Nephrol. Dial Transplant 2003; 18: 1770-1776.
58. Noonan W, Nakane M, et al: Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol. Dial Transplant 2008; 23: 3824-3830.
59. Weishaar RE, Kim SN, Saunders DE, Simpson RU, et al: Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: 134-142.
60. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 1993; 264: 1998-2006.
61. Schlter KD, Weber M, Piper HM: Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J 1995; 310:439-444.
62. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E: Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 1988; 33: 804-811.
63. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994; 4: 1814-1819.
64. Stefenelli T, Abela C, Hebert F, et al: Cardiac abnormalities in patients with primary hyperparathyroidism: implications for followup. J Clin Endocrinol Metab 1997; 82: 106-112.
65. Piovesan A, Molineri N: Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-328.
66. Nuzzo V, Tauchmanovà L, Fonderico F, Trotta R, Fittipaldi MR, Fontana D, Rossi R, Lombardi G, Trimarco B, Lupoli G: Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002; 147: 453-459.
67. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Wlodarczyk Z, Manitus J: Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001; 23: 115-126.
68. Chow KM, Szeto CC, Kum LC, et al: Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. J Nephrol. 2003; 16: 878-885.
69. Fellner SK, Lang RM, Neumann A, Bushinsky DA, Borow KM: Parathyroid hormone and myocardial performance in dialysis patients. Am J Kidney Dis 1991; 18: 320-325.
70. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
71. Elder G, Faull R, Branley P, Hawley C: Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006;11(suppl 1):230-261.
72. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF: Vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
73. Fujii H, Kim JI, Abe T, et al: Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis management. Intern Med 2007;46:1507-1512.